375853-85-3

Basic information

• Product Name: [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER;[(3-Bromo-4-fluorophenyl)methyl]-carbamic acid tert-butylester
• CAS NO: 375853-85-3
• Molecular Formula: C₁₂H₁₅BrFNO₂
• Molecular Weight: 304.16
• Mol File: 375853-85-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 375.7°Cat760mmHg
• Flash Point: 181°C
• Appearance: /
• Density: 1.376g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.521
• CAS DataBase Reference: [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER(375853-85-3)
• EPA Substance Registry System: [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER(375853-85-3)

Safety Data

• Hazardous Substances Data: 375853-85-3(Hazardous Substances Data)

Usage

General Description

[(3-Bromo-4-fluorophenyl)methyl]-carbamic acid tert-butyl ester, also known as Letermovir, is a chemical compound that is used as an antiviral medication. It works by inhibiting the replication of human cytomegalovirus (HCMV) by targeting the viral terminase complex. [(3-BROMO-4-FLUOROPHENYL)METHYL]-CARBAMIC ACID TERT-BUTYL ESTER is particularly effective in preventing HCMV infection in patients undergoing hematopoietic stem cell transplantation. It is administered orally or intravenously and is well-tolerated with minimal adverse effects. This chemical has shown promising results in clinical trials and has the potential to be a valuable treatment option for individuals at risk of HCMV infection.

InChI:InChI=1/C12H15BrFNO2/c1-12(2,3)17-11(16)15-7-8-4-5-10(14)9(13)6-8/h4-6H,7H2,1-3H3,(H,15,16)

Upstream product

• 202865-68-7 3-bromo-4-fluoro-benzylamine hydrochloride 
• 3236-56-4 dipercarbonate de O,O-t-butyle 
• 24424-99-5 di-tert-butyl dicarbonate 
• 388072-39-7 3-bromo-4-fluoro-benzylamine 

Downstream Products

• 216873-74-4 [(3-bromo-4-fluorophenyl)methyl]methylamine 
• 1188428-66-1 tert-butyl 3-cyclopropyl-4-fluorobenzylcarbamate 

Relevant articles and documents

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.